广济药业(000952) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2024 was ¥296,456,091.34, a decrease of 13.80% compared to ¥343,911,715.83 in the same period last year[11]. - The net profit attributable to shareholders was -¥106,645,331.52, representing a decline of 313.28% from -¥25,804,539.22 in the previous year[11]. - The basic earnings per share were -¥0.3014, a decline of 313.44% from -¥0.0729 in the same period last year[11]. - The diluted earnings per share were also -¥0.3014, reflecting the same percentage decline as the basic earnings per share[11]. - The company's operating revenue for the reporting period was ¥296,456,091.34, a decrease of 13.80% compared to ¥343,911,715.83 in the previous year, primarily due to a decline in VB2 sales[22]. - The company's operating costs decreased by 6.68% to ¥222,070,922.41 from ¥237,969,742.97, reflecting improved cost management[22]. - The company reported a net cash flow from operating activities of -¥114,680,947.26, an improvement of 23.41% compared to -¥149,728,835.88 in the previous year, driven by increased sales collections[22]. - The company reported a total of 410,366,534.84 yuan in long-term payables, which is 13.16% of total liabilities, reflecting a 2.09% increase from the previous year[26]. - The company reported a significant increase in inventory, which rose to 403,362,783.76 yuan, representing 12.93% of total assets, up from 9.87% in the previous year[26]. - The company reported a total of CNY 932,039,095.29 in undistributed profits, slightly up from CNY 927,060,067.64[99]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,118,461,228.10, an increase of 2.94% from ¥3,029,517,090.67 at the end of the previous year[11]. - The net assets attributable to shareholders decreased by 8.14%, totaling ¥1,252,500,581.54 compared to ¥1,363,446,043.29 at the end of the previous year[11]. - The company's fixed assets decreased to 1,524,265,821.79 yuan, which is 48.88% of total assets, down from 51.92% in the previous year[26]. - Short-term loans increased to 502,882,353.00 yuan, making up 16.13% of total liabilities, a rise of 6.52% compared to the previous year[26]. - The company's long-term borrowings decreased to 260,010,000.00 yuan, accounting for 8.34% of total liabilities, down from 13.77% in the previous year[26]. - Total liabilities increased to CNY 1,843,875,673.54, up from CNY 1,637,067,663.82, representing a growth of approximately 12.6% year-over-year[96]. - Current liabilities rose to CNY 1,156,606,686.34, compared to CNY 865,866,283.65, marking an increase of about 33.6%[96]. Research and Development - Research and development investment increased by 4.73% to ¥28,423,514.81, indicating a continued focus on innovation[22]. - The company has filed 25 patent applications in the first half of 2024, including 15 invention patents, demonstrating its commitment to technological advancement[21]. - The company is committed to enhancing its research and development capabilities to improve the conversion efficiency of R&D results[37]. Market and Product Development - The company's main products include vitamin B2, B6, and pharmaceutical preparations, with a focus on the research, production, and sales of vitamin raw materials[15]. - During the reporting period, the market demand for vitamin B2 declined, leading to a decrease in sales volume and a significant drop in gross profit[17]. - The company acquired Shandong Baisheng assets, expanding its product line to include sodium VC, lactic acid, and starch series products[15]. - The company is actively expanding its market presence in the EU for genetically modified VB2 feed additives, effective from April 11, 2023[18]. - The company plans to enhance the technology of its main products to reduce costs and improve competitiveness[37]. Environmental and Social Responsibility - The company emphasizes sustainable development and environmental responsibility in its operations[37]. - Hubei Guangji Pharmaceutical Co., Ltd. obtained a wastewater discharge permit from Huanggang Ecological Environment Bureau, valid from December 29, 2020, to December 28, 2025[44]. - The company reported a total wastewater discharge of 17.52 tons for COD and 1.75 tons for ammonia nitrogen in the first half of 2024, with respective limits of ≤500 mg/L and ≤35 mg/L[47]. - The company has established a comprehensive environmental management system to monitor and control emissions[44]. - The company donated 10,000 yuan to a local primary school to support education, reflecting its commitment to social responsibility[54]. Corporate Governance and Compliance - The company has implemented a performance-based salary system for employees, linking core indicators to performance compensation[43]. - The company actively engages with shareholders and investors through various communication channels to ensure transparency and protect their rights[53]. - The company has no significant litigation or arbitration matters during the reporting period[56]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[56]. - The financial report for the half-year period was not audited[93]. Shareholder Information - The total number of shares decreased from 353,973,939 to 353,860,939 due to the repurchase and cancellation of 113,000 restricted shares[80]. - The largest shareholder, Changjiang Industrial Investment Group Co., Ltd., holds 24.75% of the shares, amounting to 87,592,065 shares[84]. - The company had a total of 31,073 common shareholders at the end of the reporting period[84]. Financial Instruments and Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission[124]. - The financial statements are prepared based on the going concern principle[125]. - The company recognizes employee compensation liabilities for wages, bonuses, and social insurance contributions in the period services are provided[179]. - The company recognizes provisions when obligations related to contingent events meet specific criteria, including the likelihood of economic outflow and reliable measurement of the obligation amount[184]. - The company’s revenue recognition policy states that revenue is recognized when control of goods or services is transferred to the customer, with specific conditions outlined for recognizing revenue over time or at a point in time[187].